The global lymphoma treatment market was valued at USD 6.94 billion in 2018 and is projected to exceed USD 21.29 billion by 2032, growing at a CAGR of 8.3% during the forecast period. North America led the market with a 47.98% share in 2018. Increased investments by key market players in long-term research and development to create a robust pipeline of products are expected to drive market growth. Lymphomas are among the most common types of blood cancers, affecting a significant portion of the population. If not treated accurately, lymphoma can lead to severe outcomes and high mortality rates. Several leading market players are currently conducting clinical trials to develop new drug candidates for various forms of lymphoma, with a particular focus on those that are harder to treat.
According to the published report by Fortune Business Insights, titled “Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (Non-Hodgkin Lymphoma, and Hodgkin Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2025–2032” the market size stood at USD 6.94 billion in 2018. The lymphoma treatment market report focuses and elaborates the definition, types, therapeutics and major players in detail. Deep analysis about lymphoma treatment market status, competition pattern, types of therapeutics available, advantages and disadvantages of available therapeutics, industry development trends, emerging treatment options and macroeconomic policies, strategies of key market players has also been studied and provided within the synopsis. From the prevalence of types of lymphoma to downstream buyers of this industry has been analyzed scientifically, the feature of product circulation and sales channel is presented as well. This report is aimed at helping companies, investors and potential shareholders along with venture capitalists establish a bird’s eye view prospect of industrial development and characteristics of the market. The report also benefits its readers by providing the unrivalled data in well-organized manner.
Tap here to continue reading: https://www.fortunebusinessinsights.com/industry-reports/lymphoma-treatment-market-100262
Market Drives: Rising Cases of Blood Cancer to Spur Market Opportunities
The increasing prevalence of cancers of different forms, including blood cancer will aid the lymphoma treatment market growth during the forecast period. The growing necessity for advanced and effective therapeutics can be a crucial factor in boosting the lymphoma treatment market trends. For instance, lymphomas usually have no to minimal symptoms till the cancer hits the last stage and, in that period, an aggressive and efficient therapeutics is required for better clinical outcomes. Furthermore, the requirement for pretreatment options to administer advanced therapeutics in patients for the treatment of lymphoma will enable healthy growth of the market in the foreseeable future. In addition, the demand for enhanced and better clinical outcomes for patients will create business opportunities for the lymphoma treatment market during the forecast period.
Market Restraint:
High costs associated with certain therapies are limiting the growth of the lymphoma treatment market in emerging regions. Despite the increasing prevalence of blood cancers, especially in these markets, the adoption of advanced treatments is restricted. One of the key factors inhibiting market growth is the high cost of therapies, particularly immunotherapies. As a result, many patients in emerging countries cannot afford these treatments, and limited access to affordable payment options further exacerbates the situation, preventing a large number of individuals from receiving the care they need.
Key Companies Featured in the Lymphoma Treatment Market Report:
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Bayer AG
- Novartis AG
- Kite Pharma, Inc. / Gilead Sciences, Inc.
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- CELGENE CORPORATION (Bristol Myers Squibb Company)
- Merck & Co., Inc.
- Kyowa Kirin Co., Ltd.
- AbbVie Inc.
- Sanofi
- Others
Regional Analysis:
Adoption of Advanced Therapeutics to Augment Growth in North America
The lymphoma treatment market in North America stood at USD 3.33 billion in 2018 and is predicted to remain dominant during the forecast period. The growing in the region is attributed to higher diagnosis and treatment rates for all these types of cancers. The increasing prevalence of lymphoma along with high adoption of advanced therapeutics will enable growth in the region during the forecast period. The rising awareness about new treatment options among patient population further favor growth in the region. In addition, the presence of major clinical stage biopharmaceutical companies along with various drugs in pipeline candidates will aid expansion in North America. The market in Europe and Asia-Pacific is projected to hold significant share in the forthcoming years owing to the new regulatory approvals of key products in the regions. The launch of advanced therapeutics, for instance, Kymriah (tisagenlecleucel) by Novartis AG and is used for the treatment of B‑cell precursor acute lymphoblastic leukemia. The presence of a large patient population along with prevalence of cancer will aid growth in Asia Pacific. However, limited healthcare expenditure of regions such as Latin America and the Middle East will restrict the growth of the market.
Key Industry Developments:
- June 2021: Bayer submitted a supplemental new drug application (sNDA) to the FDA and a marketing authorization application (MAA) to the EMA for the oncology treatment combination of copanlisib and rituximab.
- June 2021: Novartis announced strong data from the Phase II ELARA trial of Kymriah for relapsed or refractory follicular lymphoma, showing a 66% complete response rate and an 86% overall response rate with a single infusion.
- February 2021: Bristol Myers Squibb received FDA approval for its cancer immunotherapy for certain lymphomas, specifically for adults with non-Hodgkin lymphoma.